BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2013--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the following upcoming investor conferences. The
presentations will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
Cowen & Company 33rd Annual Health Care
Monday, March 4, 2013 at 1:30 p.m. Eastern Time in Boston, MA
Barclay’s Global Healthcare Conference
Wednesday, March 13, 2013 at 3:15 p.m. Eastern Time in Miami, FL
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The company’s lead program, ADCETRIS®
(brentuximab vedotin), received accelerated approval from the U.S. Food
and Drug Administration in August 2011 and approval with conditions from
Health Canada in February 2013 for two indications. In addition, under a
collaboration with Millennium: The Takeda Oncology Company, ADCETRIS
received conditional approval from the European Commission in October
2012. Seattle Genetics also has four other clinical-stage ADC programs:
SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has
collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Abbott, Agensys
(an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as
ADC co-development agreements with Agensys and Genmab. More information
can be found at www.seattlegenetics.com.
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160